Opthea Names Medical Chief, CFO

MT Newswires Live

2024/10/08

Opthea (OPT) said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.

Zamiri most recently served as Complement Therapeutics' medical chief while Reilly was previously the CFO of Amarin (AMRN).

The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2473426720"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473426720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473426720?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473426720","market":"hk","top_or_hot":-1,"title":"Opthea Names Medical Chief, CFO","media":"MT Newswires Live","content":"<html><body><p> Opthea (OPT) said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.</p><p>Zamiri most recently served as Complement <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' medical chief while Reilly was previously the CFO of Amarin (AMRN).</p><p>The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opthea Names Medical Chief, CFO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpthea Names Medical Chief, CFO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-08 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Opthea (OPT) said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.</p><p>Zamiri most recently served as Complement <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' medical chief while Reilly was previously the CFO of Amarin (AMRN).</p><p>The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPT.AU","symbol_name":"OPTHEA LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473426720","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473426720","pubTimestamp":1728389119,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Opthea  said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.Zamiri most recently served as Complement Therapeutics' medical chief while Reilly was previously the CFO of Amarin .The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPT.AU":"OPTHEA LTD","BK7508":"医药生物股","AMRN":"阿玛琳","BK7067":"生物科技","BK4139":"生物科技"},"translate_title":"Opthea任命医疗主管、首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRN":1,"OPT.AU":1,"OPT":1},"content_text":"Opthea (OPT) said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.Zamiri most recently served as Complement Therapeutics' medical chief while Reilly was previously the CFO of Amarin (AMRN).The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}